Literature DB >> 21140923

Update on pediatric psoriasis, Part 2: Therapeutic management.

Nanette B Silverberg1.   

Abstract

Pediatric psoriasis is an autoimmune diathesis with a complex immunologic basis. It is associated with extensive psychological morbidity and should be treated rapidly and effectively to limit psychologic effects on children. The most common trigger in childhood is upper respiratory tract infection. Once disease has occurred, treatment is based on severity and presence of joint involvement. Topical therapies include corticosteroids and calcipotriene. UV light, systemic retinoids, and cyclosporine remit cutaneous psoriatic lesions. Methotrexate sodium and etanercept benefit both skin and joint manifestations of psoriasis. Concern for psychological symptoms and psychological growth is needed in treating pediatric patients with psoriasis vulgaris.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21140923

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  2 in total

1.  Safety and efficacy of fixed-dose combination calcipotriol (50 μg/g) and betamethasone dipropionate (0.5 mg/g) cutaneous foam in adolescent patients (aged 12 to <17 years) with plaque psoriasis: results of a phase II, open-label trial.

Authors:  M Seyger; W Abramovits; M Liljedahl; M N Hoejen; J Teng
Journal:  J Eur Acad Dermatol Venereol       Date:  2020-02-19       Impact factor: 6.166

Review 2.  Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives.

Authors:  Federico Diotallevi; Oriana Simonetti; Giulio Rizzetto; Elisa Molinelli; Giulia Radi; Annamaria Offidani
Journal:  Int J Mol Sci       Date:  2022-09-22       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.